SB-699551 is a drug which was the first compound developed to act as a selective antagonist for the serotonin receptor 5-HT5A, with selectivity of around 100x over other serotonin receptor subtypes.[1] Multiple therapeutic roles have been suggested for 5-HT5A ligands due to the presence of this receptor in several areas of the brain, but research is still at an early stage,[2] In animal studies, SB-699551 was found to block cue-mediated responding to LSD, again suggesting an antipsychotic type of activity.[3] It also reduces the viability of certain types of cancer cells in vitro, suggesting the 5-HT5A receptor as a possible target for novel chemotherapy drugs.[4][5]
Identifiers | |
---|---|
| |
CAS Number |
|
PubChem CID |
|
ChemSpider |
|
UNII |
|
CompTox Dashboard (EPA) |
|
Chemical and physical data | |
Formula | C34H45N3O |
Molar mass | 511.754 g·mol−1 |
3D model (JSmol) |
|
| |
| |
(verify) |